ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective.

Published in: Expert opinion on therapeutic patents (2022)

, since their main limitations were low cell penetration and low affinity to ACLY. The search for new effective ACLY inhibitors is of great significance and has broad application prospects for the treatment of hyperlipidemia and cancer.

Keyphrases

papillary thyroid
single cell
cell therapy
squamous cell
type diabetes
mesenchymal stem cells
replacement therapy
insulin resistance